Hydroxychloroquine, a chloroquine drug, has temporarily been dropped from global WHO trials for...
- IRT: A competitive advantage to accelerate clinical trials during a global pandemic and beyond
- Exploring efficiencies from eTMF with Cancer Research UK
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
‘Social responsibility’ may be reason chloroquine trials are continuing despite setbacks
Hydroxychloroquine, a chloroquine drug, has temporarily been dropped from global WHO trials for Covid-19 treatments due to safety concerns
Almac unveils advanced solution to accelerate study start-up
Almac Clinical Technologies, a unit of UK-based contract development and manufacturing firm Almac Group, has introduced an advanced interactive response technology (IRT).
Lilly starts Phase I trial of antibody therapy for Covid-19
Eli Lilly has started dosing participants in the Phase I clinical trial of antibody therapy LY-CoV555, which is intended to treat Covid-19 infection.
Global clinical trials activity decreases 11.7% in Q1 2020
Global clinical trials activity decreased by 11.7% in Q1 2020, when compared with the same quarter in 2019, according to GlobalData.
Remdesivir shows clinical improvement in Phase III Covid-19 trial
Gilead Sciences has reported positive top-line data from the Phase III SIMPLE clinical trial of remdesivir in hospitalised patients with moderate Covid-19 pneumonia.
Almac Clinical Technologies Announces Expedited Support for Covid-19 Clinical Trials
Almac Clinical Technologies has announced the expedited deployment and support of multiple Interactive Response Technology (IRT) solutions in support of Covid-19 therapies.
Minerva Neurosciences’ roluperidone fails in Phase III study
Minerva Neurosciences has reported that roluperidone failed to meet endpoints in a Phase III clinical trial for the treatment of negative symptoms in schizophrenia.
Sun Pharma to trial Nafamostat for Covid-19 treatment
Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to conduct a clinical trial of pancreatitis drug, Nafamostat Mesilate, to treat Covid-19 patients in the country.